2-(N-Propyl) 4-methyl-6-methoxycarbonylbenzimidazole (I) is an important intermediate of telmisartan pharmaceutical.3-Methyl-4-butylamino-5-aminobenzoate was efficiently converted into I in fluorous biphasic system (FBS) without acetic acid.It was found that Yb(OPf)₃ and C₁₀F₁₈ were the best catalyst and fluorous solvent resp. for the reaction.Yield of I could be up to 94% at 80° for 2 h with x [Yb(OPf)₃] = 0.3%.By simple phase separation, the fluorous phase containing only the catalyst could be directly reused next time.Based on ¹⁹F NMR and UV-Vis and GC-MS data, no loss of catalyst or fluorous solvent to the organic phase could be detected, and no organic compounds could be found in the fluorous phase.There was no significant difference between the UV-Vis spectra of the initial and recovered fluorous phases, indicating that Yb(OPf)₃ was recovered unaltered after the condensation reaction.The catalyst was completely (> 99%) recovered as determined by at. emission spectrometry.The fluorous phase containing only catalyst could be reused up to ten times with only a slight decrease in yields from 94% to 90%.

Yaowu Fenxi Zazhi

Determination of degradation products of adefovir dipivoxil by ion-pair HPLC

Author: Jiang, Fei-ying ; Zhu, Feng ; Chen, Zai-xin ; Wang, Yong-jun ; Li, Xiao-bing ; Mao, Bai-yang

A method for the determination of main degradation products including mono-POM PMEA, adefovir and other impurities in adefovir dipivoxil was established.The Welch Materials XB-C₈ column (250 mm × 4.6 mm, 5 μm) was adopted with the mobile phase consisting of buffer solution-acetonitrile (65:35), the buffer solution contained 50 mmol · L^-1 potassium phosphate dibasic and 10 mmol · L^-1 tetrabutylammonium hydrogen sulfate, and was adjusted to pH 3.0 with phosphate acid.The detection wavelength was 260 nm, and the flow rate was 1.0 mL · min^-1.The baseline separation was achieved between the main peak of adefovir dipivoxil and the near peak of impurities, and the resolutions among the main degradation products (i.e., adefovir, mono-POM PMEA and 9-[2-(diethyl-phosphonomethoxy)ethyl]adenine) were above 2.0.The good linearity was obtained over the range of 0.109-21.8 μg · mL^-1 for adefovir, 0.111-22.2 μg · mL^-1 for mono-POM PMEA, and 0.105-21.0 μg · mL^-1 for adefovir dipivoxil.The average recoveries were 98.8% for adefovir and 99.7% for mono-POM PMEA, resp.This method is simple, accurate, with well specificity, and can be applied to determination of the relative substances in adefovir dipivoxil and quality control.

100 Deals associated with Yabang Pharmaceutical Group Co Ltd

100 Translational Medicine associated with Yabang Pharmaceutical Group Co Ltd

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Yabang Pharmaceutical Group Co Ltd

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 07 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing